The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.34 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.16 — no flag raisedOK
- Earnings quality 38/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as YD Bio Ltd reports it. History and quarterly detail are in the app.
- Sales Of Medical And Other Related Products$562K
- Medical And Related Products$281K
- Drugs$223K
- Beauty Products$50K
- Research And Development Of Sales Of Contact Lenses$35K
Latest filings
- 6-K · Company announcement (foreign filer)2026-05-01
- 20-F · Annual report (foreign filer)2026-04-30
- 6-K · Company announcement (foreign filer)2026-02-26
- 6-K · Company announcement (foreign filer)2026-01-30
- 6-K · Company announcement (foreign filer)2026-01-21
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about YD Bio Ltd, every answer cited🔒
- The Intelligence Brief — added when YD Bio Ltd's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.